<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728985</url>
  </required_header>
  <id_info>
    <org_study_id>AAA 17-01</org_study_id>
    <nct_id>NCT03728985</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms</brief_title>
  <acronym>TAMBE</acronym>
  <official_title>Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, , multicenter study with two independent arms:&#xD;
&#xD;
        -  Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System.&#xD;
           Hypothesis-driven analysis.&#xD;
&#xD;
        -  Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non&#xD;
           hypothesis-driven analysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study contains two single arm substudies. A primary study arm and a secondary study arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects with Uncomplicated Technical Success and freedom from Procedural Safety Composite Event</measure>
    <time_frame>Index Procedure and Within 30 Days of Index Procedure</time_frame>
    <description>Percent of Subjects with Device Technical Success Composite Event and freedom from Procedural Safety Composite Event.&#xD;
Device Technical Success Composite Events:&#xD;
Successful Access and Delivery Successful and Accurate Deployment Successful Withdrawal&#xD;
Procedural Safety:&#xD;
Stented Segment Aortic Rupture Lesion-Related Mortality Permanent Paraplegia Permanent Paraparesis New Onset Renal Failure Requiring Dialysis Severe Bowel Ischemia Disabling Stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Subjects free from Clinically Significant Reintervention / Lesion-Related Mortality Co-Primary Endpoint Events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Aneurysm-related mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Stented Segment Aortic Rupture</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Lesion Related Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Permanent Paraplegia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Permanent Paraparesis</measure>
    <time_frame>30 days of index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with New Onset Renal Failure Requiring Dialysis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Severe Bowel Ischemia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Disabling Stroke</measure>
    <time_frame>120 days (30 Days for Initial Stroke, plus 90 Days for Followup MRS Score)</time_frame>
    <description>Stroke will be assessed using the Modified Rankin Scale. Stroke identified as having occurred within 30 days of the index endovascular procedure, combined with mRS ≥2 with an increase from baseline of at least one grade at 90 days.&#xD;
Modified Rankin Scale:&#xD;
0 - No Symptoms&#xD;
No significant disability. Able to carry out all usual activities, despite some symptoms&#xD;
Slight Disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.&#xD;
Moderate Disability. Requires some help, but able to walk unassisted&#xD;
Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.&#xD;
Severe Disability. Requires constant nursing care and attention, bedridden, incontinent&#xD;
Dead&#xD;
Higher Values are worse. A total score will not be computed, but a change from baseline will be calculated as (90 Day Post-Stroke MRS Score - Baseline MRS Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Access-Related Complications</measure>
    <time_frame>30 days of index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Procedural Blood Loss at Index Procedure</measure>
    <time_frame>Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>Index Procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Extended Technical Clinical Success</measure>
    <time_frame>30 days</time_frame>
    <description>Patients who present within the 30-Day follow-up with no Type I or Type III endoleak, as evaluated by CTA, and free from device-related intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Type I Endoleak</measure>
    <time_frame>12 Months</time_frame>
    <description>Endoleak arising from the proximal or distal sealing zone of a device perfusing the aneurysm&#xD;
Type IA: Inadequate seal at the proximal end of the device placed in the aorta&#xD;
Type IB: Inadequate seal at the distal end of the device placed in iliac vessel&#xD;
Type IC: Inadequate seal at the distal end of a device placed inside branch vessel Reported as ratio with the number of subjects with Type I Endoleak as numerator, number of subjects with an evaluable result as denominator. Ratios of Type IA, IB, and IC will also be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Type II Endoleak</measure>
    <time_frame>12 Months</time_frame>
    <description>Endoleak arising from a patent branch vessel perfusing the aneurysm, e.g., lumbar or inferior mesenteric branch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Type III Endoleak</measure>
    <time_frame>12 Months</time_frame>
    <description>Type III Endoleak through 12 months - Endoleak arising from the component junction(s) of the prosthesis or due to damage to the graft material perfusing the aneurysm.&#xD;
Type III General: A Type III endoleak whose source cannot be differentiated between an intercomponent junction or graft tear&#xD;
Type IIIA: Modular disconnection or apposition failure&#xD;
Type IIIB: Graft tear</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Type IV Endoleak</measure>
    <time_frame>12 Months</time_frame>
    <description>Endoleak of whole blood through the graft fabric perfusing the aneurysm&#xD;
Reported as a ratio. Numerator: Number of Subjects with Type IV Endoleak. Denominator: Number of Subjects with an Evaluable Result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Type IV Indeterminate Endoleak</measure>
    <time_frame>12 Months</time_frame>
    <description>Endoleak perfusing the aneurysm without a definitive source&#xD;
Reported as a ratio. Numerator: Number of Subjects with Type IV Endoleak. Denominator: Number of Subjects with an Evaluable Result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Device Migration</measure>
    <time_frame>12 Months</time_frame>
    <description>Longitudinal movement of all or part of the device for a distance ≥10 mm, as confirmed by CT scan, relative to anatomical landmarks and device positioning at the first post-operative CT scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subject with Thoracoabdominal Aneurysm (TAAA) Enlargement</measure>
    <time_frame>12 Months</time_frame>
    <description>An increase in the maximum aneurysm diameter of 5 mm or more relative to the first post-operative CT scan within the 30 day follow-up window</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Severe Distal Thromboembolic Events</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Aortic Rupture</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Device or procedure-related laparotomy</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Conversion to Open Repair</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Aortoiliac device limb occlusion</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Loss of device integrity</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as any of the following:&#xD;
Wire fracture identified in the sealing row stents of either the aortic, branch or iliac components&#xD;
Transient (compression) or permanent stent-graft collapse (invagination) following complete device deployment, resulting in an overall reduction in the aortic, branch or iliac vessel luminal diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Reintervention</measure>
    <time_frame>12 Months</time_frame>
    <description>An additional unanticipated interventional or surgical procedure (including conversion to open surgery), related to the device (including withdrawal of the delivery system) or procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Primary Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Blood flow without occlusion maintained through the device after implant without an intervention. Assisted Primary Patency through 12 Months- Blood flow maintained through the device after implant regardless of re-interventions performed (without occlusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Secondary Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Blood flow through the device regardless of reinterventions performed (with or without occlusion) and freedom from surgical bypass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Acute Kidney Injury</measure>
    <time_frame>30 Days</time_frame>
    <description>&gt;50% decrease in eGFR within 30 day follow-up window of TAMBE Device treatment when compared to pre-treatment serum creatinine value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects with Renal function deterioration</measure>
    <time_frame>12 Months</time_frame>
    <description>A sustained &gt;25% decrease in eGFR over two consecutive study visits following TAMBE Device treatment when compared to pre-treatment serum creatinine value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Thoracoabdominal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Primary Study Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secondary Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis</intervention_name>
    <description>Endovascular Aortic Stent-Graft</description>
    <arm_group_label>Primary Study Arm</arm_group_label>
    <arm_group_label>Secondary Study Arm</arm_group_label>
    <other_name>TAMBE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aortic aneurysm involving the visceral vessels requiring treatment defined as at least&#xD;
             one of the following:&#xD;
&#xD;
               -  Fusiform aneurysm diameter ≥ 5 cm&#xD;
&#xD;
               -  Saccular aneurysm (no diameter requirement)&#xD;
&#xD;
               -  Rapid aneurysm growth (≥ 5 mm in one year)&#xD;
&#xD;
          2. Aortic aneurysm that involves the abdominal aorta, with:&#xD;
&#xD;
               -  Involvement of at least one visceral vessel and aneurysmal extension as far as 65&#xD;
                  mm proximal to the celiac artery, and/or&#xD;
&#xD;
               -  No normal aorta between the upper extent of aneurysm and renal artery(s)&#xD;
&#xD;
          3. Adequate access for TAMBE Device components (femoral, axillary, and / or brachial&#xD;
             arteries as required)&#xD;
&#xD;
          4. Age ≥ 19 years at the time of informed consent signature&#xD;
&#xD;
          5. Male or infertile female&#xD;
&#xD;
          6. Patient assessment favors an endovascular approach when compared to open surgical&#xD;
             repair, as deemed by the treating physician&#xD;
&#xD;
          7. Capable of complying with protocol requirements, including follow-up&#xD;
&#xD;
          8. An Informed Consent Form signed by Subject or legal representative&#xD;
&#xD;
          9. Sufficient distal landing zones in both iliac arteries, with at least one patent&#xD;
             internal iliac artery and without planned placement of a branched iliac device, or&#xD;
             planned coverage/occlusion/embolization of any patent internal iliac artery.&#xD;
&#xD;
         10. Appropriate aortic anatomy to receive the TAMBE Device defined as all of the&#xD;
             following:&#xD;
&#xD;
               -  For the TAMBE aortic component, proximal aortic landing zone diameters between&#xD;
                  22-34 mm&#xD;
&#xD;
               -  Proximal seal zone ≥ 20 mm in length&#xD;
&#xD;
               -  Aortic neck angle ≤ 60°&#xD;
&#xD;
               -  Distal landing zone (iliac arteries) 8-25 mm&#xD;
&#xD;
               -  Distal seal zone in iliac arteries of at least 10 mm in length&#xD;
&#xD;
               -  Renal artery landing zone diameters between 4-10 mm&#xD;
&#xD;
               -  Celiac and superior mesenteric artery landing zone diameters between 5-12 mm&#xD;
&#xD;
               -  ≥ 15 mm landing zone in each branch vessel&#xD;
&#xD;
               -  Landing zones in the proximal and distal aorta and all branch vessels cannot be&#xD;
                  aneurysmal, heavily calcified, or heavily thrombosed&#xD;
&#xD;
               -  Patent left subclavian artery&#xD;
&#xD;
             Secondary Study Arm Only:&#xD;
&#xD;
         11. If aneurysm extends greater than 65 mm above celiac artery, proximal extension with a&#xD;
             CTAG Device is required. The aortic landing zone diameter treatment range with the&#xD;
             CTAG Device is 19.5-32 mm&#xD;
&#xD;
         12. The most proximal aspect of the aneurysm is at least 2.0 cm distal to the left&#xD;
             subclavian artery.&#xD;
&#xD;
         13. The most proximal aortic device seal zone will be within native aorta or a&#xD;
             previously-deployed TAG or CTAG Device • Placement inside a Dacron graft or another&#xD;
             device manufacturer's stent graft will not be supported&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The patient is / has:&#xD;
&#xD;
          1. Prior open, aortic surgery of the ascending aorta or aortic arch&#xD;
&#xD;
          2. Ruptured or leaking aortic aneurysm&#xD;
&#xD;
          3. Aneurysmal dilatation due to chronic aortic dissection&#xD;
&#xD;
          4. Infected aorta&#xD;
&#xD;
          5. Mycotic aneurysm&#xD;
&#xD;
          6. Life expectancy &lt;2 years&#xD;
&#xD;
          7. Myocardial infarction or stroke within 1 year of treatment (staged or index procedure)&#xD;
&#xD;
          8. Systemic infection which may increase risk of endovascular graft infection&#xD;
&#xD;
          9. Degenerative connective tissue disease, e.g. Marfan's or Ehler-Danlos Syndrome&#xD;
&#xD;
         10. Participation in an investigational drug study (within 30 days of last administration)&#xD;
             or investigational medical device study (within 1 year of implant) from the time of&#xD;
             study screening&#xD;
&#xD;
         11. History of drug abuse, e.g. cocaine or amphetamine or alcohol, within 1 year of&#xD;
             treatment&#xD;
&#xD;
         12. Tortuous or stenotic iliac and / or femoral arteries and the inability to use a&#xD;
             conduit for vascular access&#xD;
&#xD;
         13. A branch vessel(s) that is dissected or has significant calcification, tortuosity,&#xD;
             thrombus formation that would interfere with device delivery or ability to exclude&#xD;
             from blood flow&#xD;
&#xD;
         14. Known sensitivities or allergies to the device materials&#xD;
&#xD;
         15. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known&#xD;
             hypersensitivity to heparin&#xD;
&#xD;
         16. Patient has body habitus or other medical condition which prevents adequate&#xD;
             fluoroscopic and CT visualization of the aorta&#xD;
&#xD;
         17. Renal Insufficiency (creatinine value &gt; 1.8 mg/dL, GFR &lt; 30, or patient undergoing&#xD;
             dialysis)&#xD;
&#xD;
         18. Known concomitant aneurysm of the ascending aorta or aortic arch anticipated to&#xD;
             require surgical intervention within one year of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Farber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Ellis-Herr</last_name>
    <phone>80-437-8181</phone>
    <email>AAA1701@wlgore.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Bigelow</last_name>
    <phone>800-437-8181</phone>
    <email>AAA1701@wlgore.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Beck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Meltzer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sukgu Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Azizzadeh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Hua</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lee</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute - MedStar Washington Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javairiah Fatima</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida - Gainesville</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Back</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dean Arnaoutakis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Jordan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hoel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raghu Motaganahalli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahab Toursavadkohi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Eagleton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan - Cardiac Surgery</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Himanshu Patel</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Essentia Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bunch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Vascular Surgery - Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Manunga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardo Mendes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Sanchez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjoern Suckow</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rami Tadros</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Connolly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Stoner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Farber, MD</last_name>
      <phone>919-966-3391</phone>
      <email>mark_farber@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanger Heart &amp; Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Arko</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Charles Hughes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Lyden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timur Sarac</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nimesh Desai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPP Heart and Vascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Makaroun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tennessee -University Vascular Surgeons</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McNally</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiothoracic and Vascular Surgeons, PA (CTVS)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazin Foteh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Shutze</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75352</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Timaran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Coselli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alan Lumsden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naveed Saqib</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Panneton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic Hospitals</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Adams</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Sweet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dai Yamanouchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care, Metro Inc.</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Mewissen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SEH 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Said Abisi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital, Imperial College Healthcare, NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Gibbs</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Thoracic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

